Please use this identifier to cite or link to this item: https://doi.org/10.1186/bcr3495
Title: Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment
Authors: Li, J 
Czene, K
Brauch, H
Schroth, W
Saladores, P
Li, Y
Humphreys, K
Hall, P
Keywords: cytochrome P450 2D6
tamoxifen
antineoplastic hormone agonists and antagonists
tamoxifen
adult
aged
article
body mass
breast cancer
enzyme polymorphism
female
follow up
genetic variability
human
major clinical study
mammographic density
mammography
quantitative trait
treatment response
breast tumor
congenital malformation
genetic polymorphism
genetics
genotype
mammary gland
mammographic density
metabolism
middle aged
pathology
prognosis
risk factor
treatment outcome
Aged
Antineoplastic Agents, Hormonal
Breast Neoplasms
Cytochrome P-450 CYP2D6
Female
Genotype
Humans
Mammary Glands, Human
Middle Aged
Polymorphism, Genetic
Prognosis
Risk Factors
Tamoxifen
Treatment Outcome
Issue Date: 2013
Citation: Li, J, Czene, K, Brauch, H, Schroth, W, Saladores, P, Li, Y, Humphreys, K, Hall, P (2013). Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment. Breast Cancer Research 15 (5) : R93. ScholarBank@NUS Repository. https://doi.org/10.1186/bcr3495
Rights: Attribution 4.0 International
Abstract: Introduction: Not all breast cancer patients respond to tamoxifen treatment, possibly due to genetic predisposition. As tamoxifen-induced reductions in percent mammographic density (PMD) have been linked to the risk and prognosis of breast cancer, we conducted a candidate gene study to investigate the association between germline CYP2D6 polymorphisms and PMD change.Methods: Baseline and follow-up mammograms were retrieved for 278 tamoxifen-treated subjects with CYP2D6 metabolizer status (extensive (EM), heterozygous extensive/intermediate (hetEM/IM) or poor metabolizer (PM)). Logistic regression analyses were conducted comparing subjects who experienced >10% reduction in PMD to those who experienced ?10% reduction or increase.Results: After multivariate adjustment, PMD change was found to be significantly associated with the degree of CYP2D6 enzyme functionality (Ptrend = 0.021). Compared with EM, hetEM/IM and PM were 72% (95% confidence interval (CI): 0.10 to 0.79) and 71% (0.03 to 2.62) less likely to experience a >10% reduction, respectively.Conclusions: Tamoxifen-induced change in PMD appears to have a genetic component. © 2013 Li et al.; licensee BioMed Central Ltd.
Source Title: Breast Cancer Research
URI: https://scholarbank.nus.edu.sg/handle/10635/183197
ISSN: 14655411
DOI: 10.1186/bcr3495
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_bcr3495.pdf600.87 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

7
checked on Apr 15, 2021

Page view(s)

47
checked on Apr 15, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons